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The blood brain barrier (BBB) is a highly dynamic interface between the central nervous sys-
tem (CNS) and periphery.The BBB is comprised of a number of components and is part of
the larger neuro(glio)vascular unit. Current literature suggests that psychostimulant drugs
of abuse alter the function of the BBB which likely contributes to the neurotoxicities asso-
ciated with these drugs. In both preclinical and clinical studies, psychostimulants including
methamphetamine, MDMA, cocaine, and nicotine, produce BBB dysfunction through alter-
ations in tight junction protein expression and conformation, increased glial activation,
increased enzyme activation related to BBB cytoskeleton remodeling, and induction of
neuroinflammatory pathways. These detrimental changes lead to increased permeability
of the BBB and subsequent vulnerability of the brain to peripheral toxins. In fact, abuse
of these psychostimulants, notably methamphetamine and cocaine, has been shown to
increase the invasion of peripheral bacteria and viruses into the brain. Much work in this
field has focused on the co-morbidity of psychostimulant abuse and human immunode-
ficiency virus (HIV) infection. As psychostimulants alter BBB permeability, it is likely that
this BBB dysfunction results in increased penetration of the HIV virus into the brain thus
increasing the risk of and severity of neuro AIDS.This review will provide an overview of the
specific changes in components within the BBB associated with psychostimulant abuse as
well as the implications of these changes in exacerbating the neuropathology associated
with psychostimulant drugs and HIV co-morbidity.
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INTRODUCTION
The blood brain barrier (BBB) is a specialized structure formed
by brain endothelial cells (BECs) that are tightly interconnected
to form a boundary between the central nervous system (CNS)
and periphery (Abbott et al., 2010). Once thought to be static,
the BBB is now known to be an active and dynamic interface
that responds to signals from both the brain parenchyma and
vasculature. BBB dysfunction contributes to the pathophysiology
of numerous CNS disorders including Alzheimer’s disease (AD),
Parkinson’s disease (PD), multiple sclerosis, ischemia, and neu-
roAIDS (Stewart et al., 1992; Nath et al., 2001; Samii et al., 2004;
Compston and Coles, 2008; Yenari and Han, 2012). Recent evi-
dence points to the ability of drugs of abuse (e.g., stimulants)
to disrupt BBB function. This review will provide an overview
of normal BBB structure and function, focusing on the regula-
tion of neuroinflammation, and will provide examples of BBB
disruption specifically associated with stimulant drug abuse. As
neuroAIDS is exacerbated by stimulant abuse, we will also dis-
cuss the implications of stimulant-induced BBB dysfunction as it
relates to neuroAIDS disease progression.
COMPONENTS OF THE BBB
The structure of the BBB has been thoroughly described in other
reviews (Sandoval and Witt, 2008; Carvey et al., 2009). In brief, the
BBB is comprised of highly specialized BECs which interact with
pericytes, the vascular basement membrane, and astrocytes (Diaz-
Flores et al., 1991; Krueger and Bechmann, 2010). BECs are closely
associated through cell–cell complexes of tight junction proteins:
claudins, occludins, and junctional adhesion molecules (JAMs;
Hawkins and Davis, 2005). Adherens junctions also form between
BECs. Accessory proteins like zona occludins (ZO), cingulin, and
afadin (AF-6) provide structural support and stability to both
tight and adherens junctions (Yamamoto et al., 1999; Mark and
Davis, 2002). Though little is known about pericyte involvement
within the BBB, these cells likely regulate cerebral blood flow (Ban-
dopadhyay et al., 2001) and stabilize forming vessels (Ramsauer
et al., 2002). BECs and pericytes are enveloped by extracellular
matrix proteins that comprise the basement membrane (Farkas
and Luiten, 2001). Astrocytes interact with components of the
BBB through their foot processes that make contact with BECs to
form the glia limitans perivascularis as well as the basement mem-
brane (Krueger and Bechmann, 2010). Astrocytic foot process in
the margin of the brain form a thin membrane called the glia limi-
tans superficialis in the subarachnoid space. These two glia limitans
are classically viewed as continuous, starting at the subarachnoid
space, and merging with the parenchymal limitans as vessels pene-
trate into brain. Astrocytes facilitate BBB development by inducing
tight junction formation, providing microvascular support, and
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allowing molecule (e.g., water, sugar, ions) diffusion into the brain
(Janzer and Raff, 1987; Madsen and Hirschberg, 2010).
NEUROVASCULAR COUPLING AT THE BBB INTERFACE
There is a complex relationship between vascular and neuronal sys-
tems within the CNS. These interactions are promoted by the BBB,
neurons, and glia, which together make up the neuro(glio)vascular
unit (Hawkins and Davis, 2005; Koehler et al., 2009). This neu-
rovascular coupling regulates cerebral blood flow enabling efficient
oxygen and nutrient supply to various cell types and brain regions
(Iadecola, 2004). Moreover, intracellular communication within
the neuro(glio)vascular unit allows for localized control of cere-
bral blood flow to match the needs of specific brain regions. These
interactions are important for blood flow to the neurons, as well
as for the development, and maintenance of the neurovasculature.
FUNCTIONS OF THE BBB
The main function of the BBB is to maintain homeostasis of the
brain. This barrier protects the CNS from peripheral toxins within
the circulation. These toxins may be endogenous factors or exoge-
nous xenobiotics (Abbott et al., 2010). The impenetrability of
the BBB results from physical restriction due to tight junction
connectivity of BECs, transport regulation limiting transcellu-
lar migration, and enzymatic activities of BECs that metabolize
harmful substances at the vascular face of the BBB (Madsen and
Hirschberg, 2010).
Transport of molecules across the BBB is strictly regulated. A
wide range of lipid-soluble molecules passively diffuse through
BECs and certain molecules and cells are capable of paracellular
migration between adjacent BECs. Most molecules are restricted
either by lipid-solubility, polarity, or size, and thus require trans-
porters to cross the BBB. Transporters found within the BBB
are numerous, but in general, transporters can be categorized as
being ion transporters, active transporters (e.g., P-glycoprotein),
sodium-dependent transporters, or sodium-independent trans-
porters (Carvey et al., 2009). These transport systems supply nutri-
ents to the brain from the blood and remove metabolic byproducts
from the brain to the blood for elimination (Ohtsuki, 2004).
Through neurovascular coupling, the BBB regulates cerebral
blood flow. Contractile proteins identified in pericytes are thought
to alter vascular diameter and cerebrovascular blood flow (Ban-
dopadhyay et al., 2001). Transport systems bring in vasoactive
factors from the periphery that interact with smooth muscle
cells and pericytes surrounding the BBB endothelium to allow
for vasodilation or constriction (Peppiatt et al., 2006; Bell et al.,
2010). Additionally, cells within the neuro(glio)vascular unit can
secrete local vasoregulators like norepinephrine, nitric oxide, and
endothelin which regulate regional cerebral blood flow (Lecrux
and Hamel, 2011).
Inflammatory cells and signaling factors from the periphery
into the CNS are trafficked across the BBB. The neuroinflam-
matory responses produced by these cells and factors can also
alter BBB function and stability. While it is yet to be determined
whether BBB dysfunction occurs prior to neuroinflammation
or vice versa, studies have clearly shown that the inflamma-
tory response by resident neuroglia perpetuates BBB dysfunc-
tion and this BBB dysfunction increases the neuroinflammatory
response. Under normal physiological conditions, the BBB limits
the entry of most leukocytes into the CNS. However, select leuko-
cytes like neutrophils, can cross the BBB during normal immune
surveillance with little disruption to BBB tight junctions (Petty
and Lo, 2002). During a neuroinflammatory response, immune
factors, and endothelial adhesion molecules signal to increase
immune cell migration through the BBB (Petty and Lo, 2002).
Signals resulting in increased immune cell migration can alter
the structural organization of tight junction proteins and lead
to actin cytoskeleton remodeling in the BBB basement mem-
brane (Deli et al., 1995; Couraud, 1998; Ransohoff et al., 2003).
Migrating peripheral immune cells disrupt normal BBB function,
and produce cytokines and chemokines within the CNS which
furthers BBB disruption (Cartier et al., 2005). Cytokines [e.g.,
tumor necrosis factor alpha (TNFα), interleukin (IL)-1β and IL-6]
and the CCL2 chemokine are increased in serum, neuronal tis-
sue, and cerebrospinal fluid in several CNS disorders including
traumatic brain injury (Morganti-Kossman et al., 1997), HIV-
associated encephalitis (Cartier et al., 2005), and Huntington
disease (Stolp and Dziegielewska, 2009). These neuroinflamma-
tory factors likely contribute to BBB breakdown occurring in
these disorders through activity at their receptors on BECs and
other BBB cell types (Buckner et al., 2006). Peripheral immune
cells can also trigger increased production of inflammatory factors
(Verma and Szmitko,2006; Fletcher et al., 2009),neurotransmitters
(e.g., glutamate), neurotrophic factors (e.g., vascular endothe-
lial growth factor), and proteases (e.g., matrix metallopeptidase
(MMP-9; Petty and Lo, 2002) from BECs and astrocytes. These
factors perpetuate neuroinflammation, and contribute to contin-
uing alterations to the BBB (Petty and Lo, 2002). Alterations in
BBB integrity resulting from neuroinflammation produce a cas-
cade resulting in further BBB disruption and increased penetration
of immune cells into the CNS. This feed-forward cycle can lead
to disruptions in physiological functions of the BBB normally in
place to protect against peripheral toxins and xenobiotics, allow
for cross-barrier transport, and regulate cerebral blood flow.
Many abused drugs, including stimulants,are pro-inflammatory
which leads to BBB disruption and propagates the cyclic rela-
tionship between neuroinflammation and BBB damage. This may
accelerate the onset of the neurotoxicities associated with chronic
use of these potent drugs (Czub et al., 2001; Nath et al., 2002). This
review focuses on the effects of psychostimulant drugs though
many of the molecular and cellular mechanisms of BBB dys-
function and neuroinflammation have been well-characterized in
studies focused on the CNS depressant alcohol (see reviews: de la
Monte et al., 2009; Perdisky et al., 2011; Strazza et al., 2011).
STIMULANT DRUGS AND THE BBB
METHAMPHETAMINE
Current surveys estimate that approximately 13 million people
ages 12 and older have abused methamphetamine (meth) in their
lifetimes, making it the second most widely abused illicit drug in
the United States after cannabis (NSDUH 2011; United Nations
Office on Drugs and Crime 2007). Meth reverses the transport
of norepinephrine, dopamine (DA), and serotonin (5-HT) lead-
ing to excess release of these monoamines from the cytoplasm
and storage vesicles into the synapse (Rothman et al., 2001). Meth
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also prevents monoamine reuptake causing them to remain in
the synaptic cleft to increase post-synaptic receptor stimulation.
Chronic meth abuse in humans is associated with neurotoxic-
ities resulting in damage to both DA and 5-HT terminals in a
variety of brain regions (see review: Krasnova and Cadet, 2009).
Proposed mechanisms underlying meth-induced neurotoxicity
include increased reactive oxygen species (ROS) and dopamine-
quinone (DAQ) production (Kuhn et al., 2006), hyperthermia
(Kiyatkin et al., 2007), neuroinflammation (Guilarte et al., 2003),
and BBB dysfunction (Sharma and Kiyatkin, 2009). It is likely that
more than one mechanism underlies the neuronal maladaptations
and damage associated with meth abuse, and that this damage
is associated with the interaction of multiple mechanisms. For
example, oxidative stress and hyperthermia can increase BBB dys-
function which in turn, can exacerbate neuroinflammation after
meth exposure. While some studies show direct neurotoxicity
(Ricaurte et al., 1980; McCann et al., 2008) after meth exposure
without BBB disruption or neuroinflammation, these studies did
not assess changes in the BBB or in the inflammatory response
so it is uncertain whether neurotoxicity can occur independent of
BBB disruption and/or neuroinflammation.
Preclinical studies have reported BBB dysfunction in both
whole animal and in vitro models. Our laboratory recently showed
that a single intraperitoneal injection of either 3 or 9 mg/kg meth
in rats resulted in BBB damage in the prefrontal cortex and nucleus
accumbens shell, identified by punctate areas of fluorescein isoth-
iocyanate (FITC)-labeled albumin leakage (Kousik et al., 2011).
Other rodent studies also showed BBB dysfunction following
acute meth treatment marked by leakage of Evans blue into the
parenchyma or through increased IgG immunostaining (Bowyer
and Ali, 2006; Bowyer et al., 2008;Kiyatkin and Sharma, 2009,
2011; Sharma and Kiyatkin, 2009; Kuroda et al., 2010; Martins
et al., 2011). The treatment regimens varied greatly from single
doses ranging from 3–40 mg/kg to several acute doses over 24 h,
all of which compromised BBB integrity. Alterations to the BBB
occurred where meth-induced changes in DA or 5-HT levels and
terminal damage were most pronounced, including the striatum,
cortex, and hippocampus, but not in areas where monoamine lev-
els were unaffected by meth (e.g., the substantia nigra; Sharma and
Ali, 2006; Bowyer et al., 2008; Kousik et al., 2011; Martins et al.,
2011). Increased permeability across BECs after meth treatment
was also observed in vitro through dose-dependent decreases in
transendothelial electrical resistance, a method commonly used to
measure paracellular permeability (Mahajan et al., 2008; Zhang
et al., 2009; Abdul Muneer et al., 2011). Clinical studies report
increased levels of peripheral toxins, like HIV and hepatitis C
virus, in the brain parenchyma of meth-abusing humans (Nath
et al., 2001;Letendre et al., 2005, 2007; Schep et al., 2010). In fact,
70% of individuals undergoing treatment for hepatitis C in one
study were self-reported chronic meth abusers (Letendre et al.,
2007). These individuals had a higher hepatitis C viral load in
the brain than meth-naïve individuals diagnosed with hepatitis C
suggesting that meth-induced BBB dysfunction can increase viral
penetration into the CNS (Letendre et al., 2007).
Alterations in tight junction complexes can contribute to loss
of BBB integrity after meth treatment. Meth treatment decreases
the expression of ZO-1, occludin, and claudin-5 in both in vivo
and in vitro studies (Mahajan et al., 2008; Ramirez et al., 2009;
Banerjee et al., 2010; Abdul Muneer et al., 2011; Martins et al.,
2011). Additionally, meth can also alter other BBB cell types
and interactions. For example, meth increases the expression
of peptidases, like MMP-1 and MMP-9, which are involved
in degrading certain tight junction proteins to produce struc-
tural changes to the BBB basement membrane (Conant et al.,
2004). Meth also activates microglia and astrocytes within the
neuro(glio)vascular unit which may contribute to meth-induced
neurotoxicity, potentially through the secretion of inflammatory
cytokines, chemokines, and vasoactive factors (Kiyatkin et al.,
2007; Wisor et al., 2011). These structural and functional changes
within the BBB/neuro(glio)vascular unit can also result in brain
edema and disruption of proper ion flow across the barrier
(Sharma and Kiyatkin, 2009).
Neuroinflammation is a proposed mechanism underlying
meth-induced neurotoxicity and may also contribute to BBB dam-
age produced by meth. A single 30 mg/kg intraperitoneal injection
of meth increases the expression TNFα and IL-6 in the hip-
pocampus, frontal cortex, and striatum in mice (Goncalves et al.,
2008). Similar increases in TNFα, IL-1β, and IL-6 are reported
after multiple meth treatments and are potentially linked to meth-
induced microglial activation (Cadet et al., 1994; Lai et al., 2009;
Goncalves et al., 2010). Mahajan et al. (2008) showed that exposure
to 50 nM meth produced a 47% increase in the transmigration of
peripheral blood mononuclear cells using an in vitro BBB model.
Meth-induced increases in glial activation as well as TNFα and
TNF receptor expression were attenuated with pre-treatment of
indomethacin, an anti-inflammatory agent, suggesting a potential
therapeutic target for impeding meth-neurotoxicity (Goncalves
et al., 2010). In summary, neuroinflammation contributes to the
neurotoxicities seen after meth exposure and potentiates the feed-
forward cycle between neuroinflammation and BBB damage to
produce prolonged BBB damage (see Table 1 for a summary of
the effects of meth on BBB function).
Table 1 | Summary of the preclinical and clinical literature on
meth-induced BBB dysfunction.
In vitro BBB model Decreased transendothelial resistance (TEER)1,2,3
Increased leakage of FITC-Dextran2,4
Increased transmigration of PBMCs1
Increased MMP-1 activation5
Rodent models Increased leakage of FITC-labeled albumin
(FITC-LA) and Evans Blue6,7,8,9
Increased IgG penetration10,11,12
Increased edema8,13
Decreased expression of zona occludin 1 (ZO-1),
occludin, and claudin-53,4,14
Clinical studies Increased penetration of peripheral viruses like HIV
and Hepatitis C15,16
1Mahajan et al. (2008); 2Zhang et al. (2009); 3Abdul Muneer et al. (2011); 4Ramirez
et al. (2009); 5Conant et al. (2004); 6Kousik et al. (2011); 7Martins et al. (2011);
8Sharma and Kiyatkin (2009); 9Kiyatkin and Sharma (2011); 10Sharma andAli (2006);
11Bowyer et al. (2008); 12Kuroda et al. (2010); 13Kiyatkin et al. (2007); 14Banerjee
et al. (2010); 15Nath et al. (2001); 16Letendre et al. (2005, 2007).
www.frontiersin.org June 2012 | Volume 3 | Article 121 | 3
Kousik et al. Psychostimulants blood brain barrier neuroinflammation
MDMA (ECSTASY)
3,4-Methylenedioxymethamphetamine (MDMA or “Ecstasy”) is
a synthetic derivative of amphetamine. There is a growing popu-
lation of MDMA abusers, particularly among young adults who
attend “raves” or private clubs (NIDA 2008). Like other amphet-
amines, MDMA increases the release of monoamines from nerve
terminals through interactions with the serotonin transporter
(SERT) and dopamine transporter (DAT; Sulzer et al., 2005).
MDMA has a higher affinity for SERT than DAT resulting in
a greater release of 5-HT than DA (Rothman and Baumann,
2003). Like meth, secondary release of glutamate may contribute
to the neurotoxic effects of MDMA (Nash and Yamamoto, 1992).
Though acute consequences of MDMA use have been well-studied,
long-term effects and potential neurotoxicities are not well known.
MDMA appears to be selectively toxic to 5-HT terminals and pro-
duces long-lasting depletions of 5-HT in the hippocampus, pre-
frontal cortex, amygdala, and striatum (Morgan and Gibb, 1980;
Ricaurte et al., 1985, 1988). Moreover, thioester metabolites of
MDMA, including 3,4-dihydroxyamphetamine (DHA), also pro-
duce long-term depletion of 5-HT (Monks et al., 2004). Though
5-HT toxicities have been identified in multiple brain areas, the
mechanisms underlying this selective toxicity remain unknown.
Recent studies suggest that BBB dysfunction may contribute
to MDMA-induced neurotoxicities. Increased leakage of Evans
Blue or trypan blue as well as increased IgG immunostaining
were reported in several cortical areas, hippocampus, cerebellum,
and striatum of rats treated acutely with MDMA (Yamamoto and
Bankson, 2005; Sharma and Ali, 2008; Torres et al., 2011). BBB
dysfunction was observed immediately following acute MDMA
treatment and up to 10 weeks following an acute injection.
Increased BBB permeability after MDMA treatment was associated
with increased parenchymal penetration of endogenous albumin
(Sharma and Ali, 2008), increased activation of astrocytes, and
microglia (Monks et al., 2004), and increased brain water content
suggesting edema (Sharma and Ali, 2008).
In addition to altering BBB permeability, MDMA increases
expression of pro-inflammatory cytokines, including IL-1β, in
brain tissue (Torres et al., 2011). These cytokines can con-
tribute to the feed-forward cycle between BBB dysfunction and
neuroinflammation. MDMA abuse also leads to oxidative stress
(Yamamoto and Bankson, 2005). MDMA-induced excess release
of DA and 5-HT results in the formation of ROS, DAQ, and toxic
metabolites from 5-HT oxidation (Quinton andYamamoto, 2006).
The accumulation of toxic free radicals increases the susceptibility
of brain tissue to ischemic injury and triggers a variety of signaling
cascades leading to BBB dysfunction, brain edema, and neuroin-
flammation (Gu et al., 2012). It is likely that the oxidative stress
and neuroinflammation produced by MDMA results in BBB dys-
function, though further research is needed to verify if MDMA has
a direct detrimental effect on the BBB (see Table 2 for a summary
of the effects of MDMA on BBB function).
COCAINE
Cocaine inhibits monoamine reuptake, particularly through bind-
ing DAT (Barnett et al., 1981). While cocaine abuse was at its
highest levels in the 1970–1980s, the United States is still the
world’s number one importer and user with approximately 1.9
Table 2 | Summary of the preclinical and clinical literature on
MDMA-induced BBB dysfunction.
Rodent models Increased leakage of Evans Blue and Trypan Blue1
Increased penetration of IgG and endogenous
albumin2
Increased edema1
Increased activation of astrocytes and other neuroglial
cells1,3
Increased expression of pro-inflammatory
cytokines2,4,5
Increased production of reactive oxygen species6,7
1Sharma and Ali (2008); 2Torres et al. (2011); 3Monks et al. (2004); 4Orio et al.
(2004); 5O’Shea et al. (2005); 6Yamamoto and Bankson (2005); 7Yamamoto and
Raudensky (2008).
million current cocaine abusers (NSDUH 2008). Cocaine abuse is
not linked to DA or 5-HT terminal damage (Bennett et al., 1993)
though cocaine can produce oxidative stress and neuroinflamma-
tion. These potentially toxic effects likely contribute to cocaine-
induced BBB dysfunction. Chronic cocaine administration
(30 mg/kg/day intraperitoneal injection) ruptures the neurovascu-
lar capillaries and basement membranes of rats (Barroso-Moguel
et al., 1997). Increased BBB permeability marked by approximately
50% more Evans Blue or sodium fluorescein leakage from blood
to brain after cocaine exposure has also been observed in rodents
(Sharma et al., 2009; Yang et al., 2010; Yao et al., 2011). Whole
animal studies are more recent in this field as most studies inves-
tigating the effects of cocaine on BBB integrity use an in vitro BBB
model comprised of brain microvascular endothelial cells and C6
astrocytes. Decreases in transendothelial electrical resistance and
increases in FITC-Dextran leakage across an endothelial mono-
layer indicates increased permeability across BECs after cocaine
treatment (Fiala et al., 1998, 2005; Zhang et al., 1998; Gandhi et al.,
2010; Yao et al., 2011). Clinical studies reveal similar BBB break-
down in the basal ganglia and increased HIV penetration into the
CNS of cocaine-abusing humans (Nath et al., 2001).
Cocaine-induced BBB dysfunction is partially characterized by
loss of, or alterations in, tight junction protein complexes (Fiala
et al., 2005, 2008). Significant decreases in ZO-1 and JAM-2 occur
in both rodents and in vitro BBB preparations (Dhillon et al.,
2008; Gandhi et al., 2010; Yao et al., 2011). Cocaine treatment also
increases gene expression of factors, including MMP-1, that con-
tribute to basement membrane actin rearrangement resulting in
stress fiber formation around cerebral vessels (Nair et al., 2004;
Fiala et al., 2005; Dhillon et al., 2008). Persistent loss of, or con-
formation changes in tight junction proteins, and reorganization
of basement membrane fibers leave the brain open to peripheral
toxin penetration leading to CNS disorders linked with cocaine
abuse (see Table 3 for a summary of the effects of cocaine on BBB
function).
Neuroinflammation induced by cocaine (through increases in
endothelial adhesion molecules and inflammatory factors) poten-
tially plays an important role in BBB dysfunction. Increases
in intracellular adhesion molecule 1 (ICAM-1), vascular cell
adhesion molecule 1 (VCAM-1), endothelial-leukocyte adhesion
molecule (ELAM or selectin-1), and platelet endothelial cell
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Table 3 | Summary of the preclinical and clinical literature on
cocaine-induced BBB dysfunction.
In vitro BBB model Decreased transendothelial resistance (TEER)1,2
Increased leakage of FITC-Dextran, Evans Blue, and
toxins1,2,3,4,5,6
Increased transmigration of peripheral blood
mononuclear cells (PBMCs) and expression of
adhesion molecules4,7,8,9,10
Decreased expression of zona occludin 1(ZO-1),
junctional adhesion molecule 2 (JAM-2), and other
tight junction proteins1,2,5,7,8
Increased expression of pro-inflammatory
cytokines3,10,11
Rodent models Increased leakage of Evans Blue and NaFl5,12
Increased edema13,14
Increased transmigration of leukocytes and
expression of adhesion molecules13,15
Decreased expression of zona occludin 1 (ZO-1)5
Clinical studies Increased penetration of peripheral viruses like HIV16
Increased transmigration of leukocytes and
expression of adhesion molecules17
1Fiala et al. (2005); 2Gandhi et al. (2010); 3Zhang et al. (1998); 4Fiala et al. (1998);
5Yao et al. (2011); 6Fiala et al. (1996); 7Fiala et al. (2008); 8Dhillon et al. (2008); 9Nair
et al. (2004); 10Gan et al. (1999); 11Lee et al. (2001); 12Yao et al. (2011); 13Barroso-
Moguel et al. (1997); 14Sharma et al. (2009); 15Chang et al. (2000); 16Nath et al.
(2001); 17Buch et al. (2011).
adhesion molecule 1 (PECAM1), have been indentified in both
preclinical studies (Fiala et al., 1998, 2005; Gan et al., 1999; Chang
et al., 2000) and in cocaine-abusing humans (Buch et al., 2011).
Increases in circulating leukocytes and cell adhesion molecules
on leukocytes have also been reported with cocaine treatment in
rodents and in vitro (Chang et al., 2000; Nair et al., 2004). Increases
in cell adhesion molecules on the BBB endothelium and on leuko-
cytes promote more leukocyte extravasation from blood to brain
(Barroso-Moguel et al., 1997; Gan et al., 1999). Indeed, cocaine
treatment in vitro results in a 100% increase in the number of
peripheral blood mononuclear cells migrating across BECs (Fiala
et al., 1998, 2008; Zhang et al., 1998). Cocaine-induced increases
in leukocyte-endothelial adhesion are accompanied by elevated
levels of pro-inflammatory cytokines and chemokines. Western
blotting and immunostaining reveal increases in the expression
of TNFα, IL-6, IL-8, nuclear factor kappa B (NFκB), activator
protein 1 (AP-1), and CCR2 (Zhang et al., 1998; Gan et al.,
1999; Lee et al., 2001; Dhillon et al., 2008). These inflamma-
tory signals are also associated with increased viral invasion of
macrophage-tropic HIV across an in vitro BBB (Fiala et al., 1996;
Zhang et al., 1998) which may explain the greater neuropathol-
ogy observed in patients co-morbid for HIV infection and cocaine
abuse (Fiala et al., 2008). The effects of cocaine on the BBB are
likely exacerbated by cocaine-induced neuroinflammation.
NICOTINE
Though the number of cigarette smokers in the United States
has been steadily on the decline since the 1960s, an estimated
45.3 million Americans are still considered daily cigarette smokers
(CDC 2010). An average cigarette yields approximately 1 mg
of absorbed nicotine, a stimulant alkaloid responsible for the
addictive-properties of cigarette smoking (Connolly et al., 2007).
Nicotine is a soluble small molecule that rapidly diffuses through
the BBB and can interact directly with nicotinic acetylcholine
receptors (nAChRs) on BECs (Le, 2003). Preclinical studies using
rodent models of acute and chronic nicotine exposure reported
compromised BBB integrity, marked by Evans blue or [14C]
sucrose leakage into brain parenchyma. This BBB disruption
occurred as early as 2 h after acute nicotine and after 6 weeks
of chronic exposure (Lin et al., 1992; Uzum et al., 1999; Venis-
nik, 2000;Hawkins et al., 2004, 2005). In vitro studies using
either brain microvascular endothelial cells alone or in combi-
nation with C6 astrocytes revealed increases of FITC-Dextran
and [14C]sucrose leakage across the cells after nicotine treat-
ment (Schilling et al., 1992; Abbruscato et al., 2002). Nicotine also
decreases transendothelial electrical resistance in an in vitro BBB
model (Hutamekalin et al., 2008; Rodriguez-Gaztelumendi et al.,
2011). This decrease in resistance is dose-dependent (0.1–100µM)
and sufficient enough to produce a 60–150% increased invasion
of Escherichia coli across brain microvascular endothelial cells
(Chen et al., 2002). Whole animal studies also revealed nicotine-
induced BBB dysfunction leading to increased transport from
blood to brain of xenobiotics like squanivir, a protease inhibitor
included in anti-retroviral therapy for HIV infection (Manda et al.,
2010a). These studies offer added insight into the consequences
of nicotine use relating to uptake of therapeutics into the CNS.
Finally, both in vitro and in vivo studies report significant loss, or
alterations in, tight junction proteins including ZO-1, claudin-3,
JAMs, and occludin (Abbruscato et al., 2002; Hawkins et al., 2004;
Hutamekalin et al., 2008; Manda et al., 2010b).
In addition to altering BBB tight junctions, nicotine affects
transport and receptor systems involved in normal BBB function.
Nicotine increases the activity of monocarboxylase and organic
cation transporters while decreasing the functional activity of
ion transporters like Na+, K+, 2Cl− co- transporter, and Na+,
K+-ATPase on BECs (Wang et al., 1994; Abbruscato et al., 2004;
Lockman et al., 2005; Paulson et al., 2006; Liou et al., 2007). Nico-
tine treatment produced a 22 and 17% decrease in Na+ and
K+-ATPase activity in the microvasculature and brain, respec-
tively (Wang et al., 1994). Nicotine also inhibited the activity
of P-glycoprotein, an important efflux transporter responsible
for impeding the entry of a range of compounds into the CNS
(Manda et al., 2010a). Changes in transport mechanisms across
the BBB can produce detrimental alterations in ion gradients
and in the nutrients available to the brain (Paulson et al., 2006;
Yang et al., 2006). Nicotine-induced alterations in ion transport
are especially injurious as changes in ion gradients lead to brain
edema lasting for up to 3 weeks after nicotine exposure as well
as increased cerebral ischemic injury (Wang et al., 1997; Paulson
et al., 2010). nAChRs on cells within the BBB are also affected
by nicotine. Chronic nicotine decreases nAChR surface expres-
sion as well as expression of certain nAChR subunits, particularly
the α2 isoform, on BECs (Wang et al., 1994; Abbruscato et al.,
2004; Lockman et al., 2005). While nicotine activity at nAChRs
on BECs alters the BBB, treatment with nAChRs antagonists (e.g.,
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mecamylamine, α-bungarotoxin, and hexamethonium) decreases
nicotine-induced BBB dysfunction. This decrease in BBB disrup-
tion was identified by attenuation of [14C]sucrose leakage into the
brain parenchyma, reversal of ZO-1 loss, and decreased Escherichia
coli invasion in an in vitro BBB model (Abbruscato et al., 2002;
Chen et al., 2002; Conklin et al., 2002; Hawkins et al., 2005; see
Table 4 for a summary of the effects of nicotine on BBB function).
Nicotine can activate inflammatory signals that directly affect
BBB integrity. Studies have highlighted the effects of nicotine on
adhesion molecules necessary for immune cell extravasation from
the blood into the brain. Nicotine enhances peripheral blood
mononuclear cell migration across cerebral vessels through a
cascade promoting increased expression of adhesion molecules
and inflammatory cytokines (Yong et al., 1997; Albaugh et al.,
2004; Bradford et al., 2011). The expression of ICAM-1, VCAM-1,
and P-selectin is increased with chronic nicotine treatment (Yong
et al., 1997; Albaugh et al., 2004). Furthermore, nicotine increases
gene expression of TNFα, IL-18, IL-1β, and chemokines including
CCL2, CCL8, and CXC3CL1 (Bradford et al., 2011). Nicotine also
decreases gene expression of anti-inflammatory factors (e.g., Bcl6,
IL-10, and CCL25; Bradford et al., 2011). These studies indicate
that nicotine increases the expression of inflammatory cytokines
and endothelial adhesion molecules and can enhance leukocyte
migration across the BBB, particularly during neuroinflammation.
Table 4 | Summary of the preclinical and clinical literature on
nicotine-induced BBB dysfunction.
In vitro BBB model Decreased transendothelial resistance (TEER)1,2
Increased leakage of FITC-Dextran,[14]Sucrose, and
toxins3,4,5
Increased transmigration of peripheral blood
mononuclear cells (PBMCs) and expression of
adhesion molecules2,6,7
Decreased expression of zona occludin 1 (ZO-1),
occludin, and cadherins2,4,8
Changes in nicotinic acetylcholine receptors
(nAChR), ion channels, and transporter
systems9,10, 11, 12
Rodent models Increased leakage of Evans Blue,[14]Sucrose, and
peripheral toxins8,12,13, 14,15
Increased edema16,17
Decreased expression of zona occludin 1 (ZO-1),
occludin, and claudin-58,12
Increased expression of pro-inflammatory
cytokines18
Changes in nAChRs, ion channels, and transporter
systems19,20,21
Increased production of reactive oxygen species
(ROS)8,22,23
1Rodriguez-Gaztelumendi et al. (2011); 2Hutamekalin et al. (2008); 3Schilling et al.
(1992); 4Abbruscato et al. (2002); 5Chen et al. (2002); 6Albaugh et al. (2004);
7Speer et al. (2002); 8Manda et al. (2010a,b); 9Liou et al. (2007); 10Yang et al.
(2006); 11Paulson et al. (2006); 12Abbruscato et al. (2004); 13Hawkins et al. (2005);
14Uzum et al. (1999); 15Lin et al. (1992); 16Wang et al. (1997); 17Paulson et al. (2010);
18Bradford et al. (2011); 19Canis et al. (2009); 20Lockman et al. (2005); 21Wang et al.
(1994); 22Gerzanich et al. (2003); 23Yong et al. (1997).
STIMULANT CO-MORBIDITY WITH HIV INFECTION
Mechanisms thought to underlie stimulant-mediated toxicities
parallel those associated with HIV infection. Indeed, the co-
morbidity of stimulant abuse and HIV is well documented. Studies
report that meth abuse is linked with enhanced frequency of
unprotected sex and increased HIV transmission (Semple et al.,
2004; Buchacz et al., 2005). Moreover, the morbidity and mortal-
ity of meth-abusing HIV-positive individuals far exceeds that seen
with either pathology alone.
HIV infects peripheral leukocytes which migrate across the
BBB, thus allowing the virus access to the CNS (An et al.,
1999). This migration occurs early in HIV infection (Risdahl
et al., 1998; Romanelli et al., 2006) though HIV-induced tox-
icity of BECs occurs throughout infection and parallels HIV
toxicity of neurons (Price et al., 2005). Once HIV-infected cells
enter the brain, HIV-produced proteins trigger neuroinflamma-
tion which can exacerbate the neuroinflammatory effects of stim-
ulant drugs. As overviewed above, stimulant drug abuse compro-
mises BBB integrity through decreases in tight junction proteins
and increases in endothelial adhesion molecules which promote
leukocyte extravasation from the blood into the brain.
Meth increases the expression of HIV co-receptors, CXCR4
and CCR5 (Nair et al., 2009), and can significantly increase HIV
replication in astrocytes (Gavrilin et al., 2002). In HIV-positive
meth abusers, meth-induced BBB dysfunction facilitates increased
transport of HIV-infected leukocytes into the brain (Liang et al.,
2008). Moreover, HIV-induced BBB damage might increase the
concentration of meth within the CNS contributing to further
meth-neurotoxicity. Co-treatment of meth and HIV protein gp120
decreases transendothelial electrical resistance across BECs more
than treatment with meth or gp120 alone (Mahajan et al., 2008).
Administration of meth and gp120 or the HIV protein Tat in
combination, further decreased the expression of ZO-1, claudin-3,
claudin-5, and JAM-2 than either treatment alone (Mahajan et al.,
2008; Banerjee et al., 2010). In addition to the effects of meth and
HIV on tight junction proteins, increased levels of MMP-2 and
MMP-9 were reported with meth and Tat treatment in an in vitro
BBB model (Conant et al., 2004) and in the cerebrospinal fluid of
HIV-positive individuals (Conant et al., 1999; Liuzzi et al., 2004).
These peptidases can produce persistent BBB damage, leaving the
brain open to prolonged infiltration of HIV and other peripheral
toxins.
Clinical investigations revealed potential additive and/or syner-
gistic effects of meth and HIV within the CNS. Chang et al. (2005)
found increased neuronal loss in frontal gray matter (−5.7%),
frontal white matter (−6.1%), and basal ganglia (−6%) when
compared with HIV-positive meth-naïve individuals and HIV-
negative meth abusers. These studies also reported increased glial
activation and changes in cellular metabolism in frontal white
matter and basal ganglia in HIV-positive meth abusers (Chang
et al., 2005). Meth-induced glial activation may lead to increased
progression of neuroAIDS in HIV-positive meth abusers (Garden,
2002). DA neurotoxicity is associated with both meth abuse, and
HIV infection appears worsened by the combination (Czub et al.,
2001; Maragos et al., 2002; Theodore et al., 2006). Increased DA
neurotoxicity with meth abuse and HIV/AIDS co-morbidity may
increase the risk of DA-associated disorders like PD. In fact, meth
abusers have a twofold increase in developing PD compared with
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healthy controls or cocaine abusers (Callaghan et al., 2012) and as
many as 10% of patients with HAND also display Parkinsonian
features (Berger and Nath, 1997). In summary, the neuropatholog-
ical features associated with both meth abuse and HIV/AIDS may
be exacerbated through meth-induced BBB dysfunction resulting
in, or worsened by, neuroinflammation.
Similar to meth abuse, individuals abusing MDMA are more
likely to engage in risky sexual behaviors and injection drug use
(Dunn et al., 2010). Indeed, 77% of participants in a clinical inves-
tigation reported not using condoms when under the influence
of MDMA, and of this group, 54% reported having two or more
sexual partners during this time (Dunn et al., 2010). In a simi-
lar clinical study, 9.3% of MDMA users surveyed reported having
unprotected sex with partners who were either HIV-positive or of
unknown HIV status (Klitzman et al., 2002). These behaviors likely
increase HIV transmission within this population (Mitcheson
et al., 2008). Little is currently known about the neurotoxic impli-
cations of MDMA and HIV co-morbidity. As MDMA produces
BBB dysfunction as well as neuroinflammation and oxidative
stress, which both perpetuate BBB damage, MDMA-induced BBB
dysfunction would be expected to increase HIV-infected leukocyte
infiltration into the CNS. The interaction between MDMA and
HIV has not yet been characterized and may represent an unknown
population at risk for HIV and MDMA-associated neurotoxici-
ties. These toxicities may be exacerbated by MDMA-induced BBB
dysfunction leading to increased HIV penetration into the brain.
Early investigations reported cocaine abuse as a risk factor
for increased HIV transmission and a more rapid progression to
AIDS (Fiala et al., 1998; Webber et al., 1999). Cocaine increases
HIV infiltration into the CNS through increased HIV-infected
leukocyte adhesion and transmigration across the BBB endothe-
lium. BBB dysfunction observed following cocaine exposure can
increase the capacity of other immune cells and inflammatory fac-
tors to enter into the brain from the periphery. These features of
cocaine likely promote the neuroinflammation associated neu-
roAIDS. Cocaine also increases HIV replication in monocytes,
macrophages, and astrocytes (Peterson et al., 1991; Roth et al.,
2002; Reynolds et al., 2006). This is especially important as astro-
cytes may act as a reservoir for HIV within the brain (Nath, 2010).
Preclinical studies revealed that cocaine enhances oxidative stress,
neuronal dysfunction, and apoptosis in gp120 and Tat-treated cells
in vitro and in rodents (Koutsilieri et al., 1997; Nath et al., 2000;
Bagetta et al., 2004). Recent findings from Napier et al. (2010)
revealed that cocaine and Tat synergize to over activate cortical
neurons. Like cocaine, Tat can inhibit DAT which may contribute
to HIV-induced DA neurotoxicity (Aksenov et al., 2008). When
combined, cocaine plus Tat may result in DA neurotoxicities which
exacerbate HIV neuropathology. Cocaine-induced BBB dysfunc-
tion leading to increased HIV transmission into the CNS is apt to
contribute to the resulting neurotoxicities associated with cocaine
and HIV co-morbidity.
There are a number of clinical reports documenting the effects
of cocaine and HIV co-morbidity. Cocaine abuse accelerates HIV
disease progression by decreasing CD4+T-cell counts and increas-
ing HIV viral load, independent of anti-retroviral therapies (Baum
et al., 2009). Chaisson et al. (1989) found that daily cocaine
use increased the risk of HIV infection up to sixfold in African
American and Hispanic populations. Persistent cocaine abusers
are also three times more likely to die from AIDS-related compli-
cations than cocaine-naïve individuals (Cook et al., 2008). This
suggests a synergistic interaction between cocaine and HIV which
exacerbates HIV disease progression. Interactions between cocaine
and HIV within the brain parenchyma may be enhanced through
cocaine-induced increases in HIV-infected leukocyte trafficking
across the BBB.
Studies report a 51% or higher cigarette smoking rate among
nationally surveyed HIV-positive individuals (Collins et al., 2001;
Gritz et al., 2004; Burkhalter et al., 2005). Though little is known
about the effects of nicotine on HIV disease progression, smok-
ing increases the likelihood of HIV-related complications (e.g.,
bacterial pneumonia and HIV-associated dementia) and increases
the mortality rate of HIV-positive individuals (Hirschtick et al.,
1995; Conley et al., 1996; Feldman et al., 2006). Furthermore,
nicotine can act as a major immunosuppressive agent by atten-
uating the immune and virological response to anti-retroviral
therapies by up to 40% (Humfleet et al., 2009). Nicotine has
both pro- and anti-inflammatory properties. The immunosup-
pressive effects of nicotine include increasing T-cell unresponsive-
ness, increasing IL-4 production, and inhibiting the production
of certain pro-inflammatory cytokines (Sopori and Kozak, 1998).
Immunosuppressive functions can add to the already detrimen-
tal immune suppression produced by HIV infection leading to
an accelerated progression of HIV-associated complications. The
pro-inflammatory effects of nicotine within the CNS include
increasing the release of pro-inflammatory cytokines and increas-
ing leukocyte transmigration through BECs from blood to brain.
Nicotine may increase HIV viral load within the CNS through
increasing BBB permeability and promoting leukocyte migration
into the brain parenchyma. Nicotine enhances the production
of HIV in macrophages (Abbud et al., 1995) and in activated
microglia (Rock et al., 2008). Similar increases in HIV replication
are also seen with opiate and cocaine abuse which are reported to
promote HIV neuropathology (Nath et al., 2002; Roth et al., 2005).
The scope of what is currently known about the effects of nicotine
on HIV disease progression is limited, though HIV-positive indi-
viduals who smoke cigarettes show a decreased immune response,
poorer responses to anti-retroviral therapies, greater risk of viral
rebound, and an increased probability for HIV-related complica-
tions (Feldman et al.,2006). Nicotine may increase HIV infiltration
into the CNS through nicotine-induced BBB dysfunction and
increase HIV replication within microglia in the brain to accelerate
progression to neuroAIDS.
CONCLUSION
The BBB/neuro(glio)vascular unit plays an important function in
the neurotoxicity of stimulant abuse; both as a factor involved
in the development of neurotoxicities and also in its response
to these toxic effects. This suggests that components within the
BBB and neuro(glio)vascular unit may be potential therapeutic
sites targeted to impede the progression of stimulant-induced
neurotoxicity. Most stimulants dysregulate the BBB through alter-
ations in tight junction complexes or through oxidative stress
and neuroinflammation. Neuroinflammation plays a particularly
important role as it contributes to a feed-forward process between
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BBB dysfunction and neuroinflammation which likely results in
the CNS being more vulnerable to infiltration of pathological
mediators from the periphery. This is especially important in co-
morbid situations of stimulant abuse and immune disorders, like
HIV/AIDS. Stimulants not only increase the migration of periph-
eral HIV-infected leukocytes into the CNS, but once inside the
brain, can accelerate the progression to neuroAIDS.
The effects of stimulant drugs have been extensively researched,
though further studies are required to advance the field toward
identification of therapeutic targets for medication development.
Preclinical studies thus far have revealed a great deal about the
direct and indirect effects of stimulants on the BBB. Future studies
must build upon what is already known using a model of stimu-
lant abuse and co-occurring morbidities, like HIV infection. Such
models of co-morbidity would better emulate the human con-
dition and would allow more direct assessments of the dynamic
interactions between all cells within the BBB/neuro(glio)vascular
unit in these clinically important human scenarios.
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